-
Here's How Much Investing $100 In Gilead Sciences Stock Back In 2010 Would Be Worth Today
Wednesday, April 29, 2020 - 12:36pm | 460Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Gilead’s Big Decade One strong...
-
Gilead Defends Hepatitis C Treatments On Reports Of Side Effects
Thursday, January 26, 2017 - 9:18am | 485Shares of Gilead Sciences, Inc. (NASDAQ: GILD) appear to be unaffected by reports that call into question the safety of hepatitis C drugs. The stock was trading higher by 0.47 percent at $72.25 ahead of Thursday's stock market open. According to Stat News, reports were filed with the U.S. Food and...
-
The 5 Top-Selling Drugs In The World
Tuesday, September 20, 2016 - 12:09pm | 488The 2016 election season has brought the topic of prescription drug pricing and profits into the limelight. Most patients paying for medication are acutely aware of the billions of dollars of global drug sales that the top pharmaceutical companies rake in each year. With the elections now less than...
-
Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings
Wednesday, July 27, 2016 - 9:12am | 379Barclays remains Overweight on Gilead Sciences, Inc. (NASDAQ: GILD) on valuation and franchise stability, despite reporting disappointing second-quarter results on the heels of hepatitis C drug Harvoni's continued sales declines. Harvoni, Sovaldi Sales for Harvoni plunged about 29 percent to $2.56...
-
Gilead Vs. Merck: What To Know
Monday, March 7, 2016 - 4:19pm | 357Gilead Sciences, Inc. (NASDAQ: GILD) and Merck & Co., Inc. (NYSE: MRK) on Monday stepped into court again, trying to settle a dispute regarding the validity of the latter's '499 and '712 patents, which Gilead’s Hepatitis C treatments Sovaldi/Harvoni were found to infringe...
-
Gilead Trounces Hep C Estimates; Harvoni International Footprint Nearly Equals U.S.
Tuesday, February 2, 2016 - 6:17pm | 200Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's post-market session after the company beat Wall Street revenue and earnings estimates handily. Perhaps more importantly to some investors, Gilead reported that sales for its Hep C drugs, Harvoni and Sovaldi, totaled $4.89...
-
Massachusetts Attorney General To Gilead Sciences: Cost Of Harvoni & Sovaldi Drugs 'May Constitute An Unfair Trade Practice In Violation Of Massachusetts Law'
Wednesday, January 27, 2016 - 3:16pm | 259According to The Boston Globe, Massachusetts Attorney General Maura Healey wrote a letter to Gilead Sciences, Inc. (NASDAQ: GILD) which suggested her office could initiate legal action. The Boston Globe noted that Healey's letter was dated January 22 and delivered to Gilead's CEO John...
-
Gilead Sciences Tumbles; Unconfirmed Reports Of Drug Pricing Changes In Japan
Wednesday, January 20, 2016 - 1:07pm | 125Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading lower by more than 2 percent at $87.87 on Wednesday following an unconfirmed report by Pharma Japan, a pharmaceutical industry news site in Japan. According to Pharma Japan, Gilead's Sovaldi and Harvoni are among a small handful of...
-
High Drug Prices Put Gilead Under Fire From Senate Committee
Wednesday, December 2, 2015 - 9:39am | 391The Wall Street Journal highlighted a U.S. Senate report on Gilead Sciences, Inc. (NASDAQ: GILD) saying that the pharmaceutical giant knew high prices for its Hepatitis C drug would put the medicine out of reach for many patients that needed the treatment. The company priced its Solvaldi...
-
Gilead Stock Whiffs, But One Pro Remains Bullish
Wednesday, October 28, 2015 - 2:26pm | 432Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading lower by more than 3 percent Wednesday afternoon. The company reported an upbeat third-quarter print, while full year guidance may have disappointed some investors. Wendy Lam of Oppenheimer maintained an Outperform rating and $...
-
China Rejects Gilead's Sovaldi Patent Application
Saturday, June 20, 2015 - 2:38pm | 509China’s State Intellectual Property Office (SIPO) has decided to reject a Gilead Sciences, Inc. (NASDAQ: GILD)’s patent application relating to its hepatitis C (HCV) drug sofosbuvir, marketed as Sovaldi. The rejection could have important implications for Gilead, its generic drug...
-
Gilead Soothes Price War Worry With Q1 Results
Friday, May 1, 2015 - 12:29pm | 535Gilead Sciences, Inc. (NASDAQ: GILD) gained more than 3 percent early in Friday's session on earnings and news that first quarter revenue from its hepatitis C treatments rose sequentially by 19 percent to well ahead of Wall Street's estimates. Shares traded recently at $105.48, up 5...
-
Is Gilead Sciences About To Buy Vertex For $45 Billion?
Thursday, April 30, 2015 - 11:57am | 498Gilead Sciences, Inc. (NASDAQ: GILD) has been rolling in the money since the release of its hepatitis C drug duo, Sovaldi and Harvoni. Now investors are wondering how Gilead will put its pile of cash to work. In its Q4 earnings report, Gilead announced that its cash position had increased from...
-
This Data Offers Insight Into Gilead Sales
Wednesday, April 8, 2015 - 12:44pm | 587Gilead Sciences, Inc. (NASDAQ: GILD) received new data from IMS Health about the breakdown of its drug prescriptions. Gilead is most known for its hepatitis C medications, Harvoni and Sovaldi. IMS prescription data breaks down how many people are receiving which drug prescriptions in more than...
-
Gilead Sciences Hovering Above Major Support Level
Tuesday, March 31, 2015 - 1:09pm | 207Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show. Gilead Sciences, Inc. (NASDAQ: GILD) shares were trading lower $1.95 at $98.74 in Tuesday's session. The decline is taking place despite the company getting approval in Japan for Sovaldi, a hepatitis C...